Symbols / MOLN Stock $4.28 -1.61% Molecular Partners AG
MOLN (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Ratings
Current target
$4.28
Low
$3.75
High
$16.99
Mean
$11.11
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-22 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2026-03-16 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2026-01-27 | init | HC Wainwright & Co. | — → Buy | $13 |
| 2025-12-08 | main | JP Morgan | Neutral → Neutral | $4 |
| 2025-09-03 | main | JP Morgan | Neutral → Neutral | $4 |
| 2025-03-11 | init | LifeSci Capital | — → Outperform | $12 |
| 2023-12-05 | main | JP Morgan | Neutral → Neutral | $5 |
| 2022-08-29 | down | SVB Leerink | Outperform → Market Perform | $8 |
| 2022-05-25 | up | Credit Suisse | Underperform → Neutral | — |
| 2022-04-27 | main | SVB Leerink | — → Outperform | $29 |
| 2022-01-14 | main | SVB Leerink | — → Outperform | $42 |
| 2021-08-27 | main | SVB Leerink | — → Outperform | $35 |
| 2021-07-13 | init | Cowen & Co. | — → Outperform | $50 |
- Molecular (MOLN) Stock: What Is Driving Performance | Molecular Partners AG ADS notches 32.5% EPS beat vs estimates - Community Watchlist - UBND thành phố Hải Phòng hu, 23 Apr 2026 05
- Biotech Molecular Partners adds dealmaker Clare Fisher to board - Stock Titan ue, 14 Apr 2026 07
- Molecular (MOLN) Stock: What Is Driving Performance | Molecular Partners AG ADS notches 32.5% EPS beat vs estimates - Low Volatility - Cổng thông tin điện tử tỉnh Lào Cai hu, 23 Apr 2026 02
- MOLN (Molecular Partners AG American Depositary Shares) posts narrower Q4 2025 loss than estimates, shares dip 0.48 percent in trading. - Social Buy Zones - Cổng thông tin điện tử tỉnh Tây Ninh Wed, 22 Apr 2026 23
- MOLN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $13 - GuruFocus Wed, 22 Apr 2026 15
- H.C. Wainwright reiterates Molecular Partners stock rating at buy By Investing.com - Investing.com South Africa Wed, 22 Apr 2026 11
- Molecular Partners AG (VTX:MOLN) is definitely on the radar of hedge funds investors who own 50% of the company - Yahoo Finance Mon, 29 Sep 2025 07
- Is Molecular (MOLN) Stock Worth Buying Now | Price at $4.10, Down 3.30% - Macro Trends - Cổng thông tin điện tử Tỉnh Sơn La hu, 09 Apr 2026 07
- New cancer data spotlight selective T-cell killing and DLL3 targeting - Stock Titan Sun, 19 Apr 2026 16
- Is Molecular (MOLN) Stock Good for Short Term | Price at $3.87, Down 4.21% - Gap Up Stocks - Cổng thông tin điện tử Tỉnh Sơn La ue, 07 Apr 2026 07
- Molecular Partners (NASDAQ: MOLN) shareholders approve all AGM items, add Clare Fisher - Stock Titan ue, 14 Apr 2026 07
- MOLN (Molecular) Q4 2025 EPS tops estimates, sending shares up nearly 5 percent in today’s session. - Regulatory Risk - Xã Châu Thành Wed, 22 Apr 2026 20
- Is Molecular (MOLN) Stock Good for Short Term | Price at $3.87, Down 4.21% - Public Sentiment - Cổng thông tin điện tử tỉnh Lào Cai ue, 07 Apr 2026 07
- Biotech board switch: Molecular Partners nominates Clare Fisher - Stock Titan Mon, 23 Mar 2026 07
- New cancer radiotherapy and immune therapies move into trials in 2026 - Stock Titan Sun, 11 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
-100.00%
|
4.97
-29.38%
|
7.04
-96.29%
|
189.56
|
| Operating Revenue |
|
0.00
-100.00%
|
4.97
-29.38%
|
7.04
-96.29%
|
189.56
|
| Operating Expense |
|
55.44
-16.24%
|
66.19
-2.87%
|
68.15
-6.58%
|
72.94
|
| Research And Development |
|
40.19
-17.30%
|
48.60
-0.37%
|
48.78
-3.87%
|
50.75
|
| Selling General And Administration |
|
14.87
-13.36%
|
17.16
-9.64%
|
19.00
-12.95%
|
21.82
|
| General And Administrative Expense |
|
14.87
-13.36%
|
17.16
-9.64%
|
19.00
-12.95%
|
21.82
|
| Salaries And Wages |
|
9.79
-10.71%
|
10.96
-5.83%
|
11.64
-1.26%
|
11.79
|
| Other Gand A |
|
5.08
-18.04%
|
6.20
-15.66%
|
7.36
-26.70%
|
10.03
|
| Other Operating Expenses |
|
—
|
—
|
—
|
-0.04
|
| Total Expenses |
|
55.44
-16.24%
|
66.19
-2.87%
|
68.15
-6.58%
|
72.94
|
| Operating Income |
|
-55.44
+9.44%
|
-61.22
-0.18%
|
-61.11
-152.40%
|
116.61
|
| Total Operating Income As Reported |
|
-58.12
+5.05%
|
-61.22
-0.18%
|
-61.11
-152.40%
|
116.61
|
| EBITDA |
|
-59.49
-15.18%
|
-51.65
+13.24%
|
-59.53
-149.26%
|
120.85
|
| Normalized EBITDA |
|
-51.78
+6.66%
|
-55.48
-1.93%
|
-54.42
-145.30%
|
120.13
|
| Reconciled Depreciation |
|
2.14
-9.50%
|
2.37
-2.11%
|
2.42
+1.34%
|
2.39
|
| EBIT |
|
-61.63
-14.10%
|
-54.02
+12.81%
|
-61.95
-152.30%
|
118.46
|
| Total Unusual Items |
|
-7.70
-301.10%
|
3.83
+175.01%
|
-5.11
-812.13%
|
0.72
|
| Total Unusual Items Excluding Goodwill |
|
-7.70
-301.10%
|
3.83
+175.01%
|
-5.11
-812.13%
|
0.72
|
| Special Income Charges |
|
-2.69
|
0.00
|
0.00
|
—
|
| Restructuring And Mergern Acquisition |
|
2.69
|
0.00
|
0.00
|
—
|
| Net Income |
|
-61.65
-14.08%
|
-54.04
+12.81%
|
-61.98
-152.59%
|
117.85
|
| Pretax Income |
|
-61.65
-14.08%
|
-54.04
+12.81%
|
-61.98
-152.59%
|
117.85
|
| Net Non Operating Interest Income Expense |
|
1.49
-55.50%
|
3.35
-20.90%
|
4.23
+708.80%
|
0.52
|
| Interest Expense Non Operating |
|
0.02
-28.00%
|
0.03
-26.47%
|
0.03
-94.38%
|
0.60
|
| Net Interest Income |
|
1.49
-55.50%
|
3.35
-20.90%
|
4.23
+708.80%
|
0.52
|
| Interest Expense |
|
0.02
-28.00%
|
0.03
-26.47%
|
0.03
-94.38%
|
0.60
|
| Interest Income Non Operating |
|
1.52
-55.02%
|
3.38
-20.92%
|
4.28
+274.69%
|
1.14
|
| Interest Income |
|
1.52
-55.02%
|
3.38
-20.92%
|
4.28
+274.69%
|
1.14
|
| Other Income Expense |
|
-7.70
-301.10%
|
3.83
+175.01%
|
-5.11
-812.13%
|
0.72
|
| Gain On Sale Of Security |
|
-5.01
-230.89%
|
3.83
+175.01%
|
-5.11
-812.13%
|
0.72
|
| Tax Provision |
|
0.00
+0.00%
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
-55.96%
|
0.00
-0.52%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.65
-301.10%
|
0.33
+133.04%
|
-0.99
-808.46%
|
0.14
|
| Net Income Including Noncontrolling Interests |
|
-61.65
-14.08%
|
-54.04
+12.81%
|
-61.98
-152.59%
|
117.85
|
| Net Income From Continuing Operation Net Minority Interest |
|
-61.65
-14.08%
|
-54.04
+12.81%
|
-61.98
-152.59%
|
117.85
|
| Net Income From Continuing And Discontinued Operation |
|
-61.65
-14.08%
|
-54.04
+12.81%
|
-61.98
-152.59%
|
117.85
|
| Net Income Continuous Operations |
|
-61.65
-14.08%
|
-54.04
+12.81%
|
-61.98
-152.59%
|
117.85
|
| Normalized Income |
|
-54.60
+5.12%
|
-57.55
+0.55%
|
-57.86
-149.34%
|
117.28
|
| Net Income Common Stockholders |
|
-61.65
-14.08%
|
-54.04
+12.81%
|
-61.98
-152.59%
|
117.85
|
| Diluted EPS |
|
-1.65
-3.77%
|
-1.59
+15.87%
|
-1.89
-153.39%
|
3.54
|
| Basic EPS |
|
-1.65
-3.77%
|
-1.59
+15.87%
|
-1.89
-152.07%
|
3.63
|
| Basic Average Shares |
|
37.27
+9.52%
|
34.03
+3.85%
|
32.77
+0.93%
|
32.47
|
| Diluted Average Shares |
|
37.27
+9.52%
|
34.03
+3.85%
|
32.77
-1.49%
|
33.27
|
| Diluted NI Availto Com Stockholders |
|
-61.65
-14.08%
|
-54.04
+12.81%
|
-61.98
-152.59%
|
117.85
|
| Depreciation Amortization Depletion Income Statement |
|
0.37
-11.46%
|
0.42
+14.17%
|
0.37
-11.78%
|
0.42
|
| Depreciation And Amortization In Income Statement |
|
0.37
-11.46%
|
0.42
+14.17%
|
0.37
-11.78%
|
0.42
|
| Total Other Finance Cost |
|
0.01
+15.38%
|
0.01
-13.33%
|
0.01
+7.14%
|
0.01
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Assets |
|
102.11
-35.59%
|
158.53
-20.08%
|
198.35
|
| Current Assets |
|
96.88
-37.21%
|
154.28
-19.84%
|
192.46
|
| Cash Cash Equivalents And Short Term Investments |
|
93.06
-37.73%
|
149.44
-20.04%
|
186.89
|
| Cash And Cash Equivalents |
|
82.65
+29.40%
|
63.87
-5.10%
|
67.31
|
| Cash Financial |
|
82.65
+29.40%
|
63.87
-5.10%
|
67.31
|
| Other Short Term Investments |
|
10.40
-87.84%
|
85.56
-28.45%
|
119.58
|
| Receivables |
|
1.91
-26.53%
|
2.59
-15.92%
|
3.08
|
| Accounts Receivable |
|
0.25
-11.54%
|
0.29
-3.05%
|
0.29
|
| Other Receivables |
|
0.15
-56.94%
|
0.35
-70.51%
|
1.20
|
| Taxes Receivable |
|
1.50
-23.23%
|
1.95
+22.74%
|
1.59
|
| Prepaid Assets |
|
1.91
-14.90%
|
2.25
-9.53%
|
2.49
|
| Other Current Assets |
|
-0.00
|
—
|
—
|
| Total Non Current Assets |
|
5.23
+23.17%
|
4.25
-27.93%
|
5.89
|
| Net PPE |
|
5.23
+24.56%
|
4.20
-26.10%
|
5.68
|
| Gross PPE |
|
25.10
+11.75%
|
22.46
+2.00%
|
22.02
|
| Accumulated Depreciation |
|
-19.87
-8.81%
|
-18.27
-11.77%
|
-16.34
|
| Properties |
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
1.84
-16.91%
|
2.21
+8.75%
|
2.03
|
| Other Properties |
|
22.63
+15.36%
|
19.62
+1.35%
|
19.36
|
| Leases |
|
0.63
+0.00%
|
0.63
+0.00%
|
0.63
|
| Goodwill And Other Intangible Assets |
|
0.00
-95.92%
|
0.05
-76.89%
|
0.21
|
| Other Intangible Assets |
|
0.00
-95.92%
|
0.05
-76.89%
|
0.21
|
| Other Non Current Assets |
|
—
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
21.77
+28.90%
|
16.89
-22.95%
|
21.92
|
| Current Liabilities |
|
11.03
+2.24%
|
10.79
-25.19%
|
14.42
|
| Payables And Accrued Expenses |
|
9.82
+2.63%
|
9.57
+7.81%
|
8.88
|
| Payables |
|
1.77
-5.00%
|
1.86
+39.98%
|
1.33
|
| Accounts Payable |
|
0.94
+38.00%
|
0.68
+65.61%
|
0.41
|
| Other Payable |
|
0.83
-29.75%
|
1.18
+28.54%
|
0.92
|
| Current Accrued Expenses |
|
8.05
+4.48%
|
7.71
+2.15%
|
7.55
|
| Employee Benefits |
|
8.15
+66.98%
|
4.88
-3.63%
|
5.06
|
| Total Tax Payable |
|
—
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
1.21
-0.90%
|
1.22
+0.75%
|
1.21
|
| Current Capital Lease Obligation |
|
1.21
-0.90%
|
1.22
+0.75%
|
1.21
|
| Current Deferred Liabilities |
|
—
|
0.00
-100.00%
|
4.33
|
| Current Deferred Revenue |
|
—
|
0.00
-100.00%
|
4.33
|
| Other Current Liabilities |
|
0.00
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
10.75
+75.99%
|
6.11
-18.66%
|
7.51
|
| Long Term Debt And Capital Lease Obligation |
|
2.44
+98.70%
|
1.23
-49.80%
|
2.44
|
| Long Term Capital Lease Obligation |
|
2.44
+98.70%
|
1.23
-49.80%
|
2.44
|
| Tradeand Other Payables Non Current |
|
0.16
|
0.00
|
—
|
| Non Current Deferred Liabilities |
|
—
|
—
|
0.00
|
| Non Current Deferred Revenue |
|
—
|
—
|
0.00
|
| Other Non Current Liabilities |
|
0.00
|
—
|
—
|
| Stockholders Equity |
|
80.33
-43.28%
|
141.64
-19.72%
|
176.43
|
| Common Stock Equity |
|
80.33
-43.28%
|
141.64
-19.72%
|
176.43
|
| Capital Stock |
|
4.04
+0.02%
|
4.04
+11.03%
|
3.63
|
| Common Stock |
|
4.04
+0.02%
|
4.04
+11.03%
|
3.63
|
| Share Issued |
|
40.37
+0.03%
|
40.36
+11.03%
|
36.35
|
| Ordinary Shares Number |
|
37.41
+1.49%
|
36.86
+12.20%
|
32.85
|
| Treasury Shares Number |
|
2.96
-15.34%
|
3.50
+0.00%
|
3.50
|
| Additional Paid In Capital |
|
389.18
+1.12%
|
384.88
+5.29%
|
365.53
|
| Retained Earnings |
|
-311.75
-26.58%
|
-246.29
-28.44%
|
-191.75
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
—
|
—
|
| Treasury Stock |
|
1.13
+15.09%
|
0.98
+0.00%
|
0.98
|
| Other Equity Adjustments |
|
—
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
80.33
-43.28%
|
141.64
-19.72%
|
176.43
|
| Total Capitalization |
|
80.33
-43.28%
|
141.64
-19.72%
|
176.43
|
| Working Capital |
|
85.85
-40.17%
|
143.50
-19.40%
|
178.04
|
| Invested Capital |
|
80.33
-43.28%
|
141.64
-19.72%
|
176.43
|
| Total Debt |
|
3.64
+49.10%
|
2.44
-33.08%
|
3.65
|
| Capital Lease Obligations |
|
3.64
+49.10%
|
2.44
-33.08%
|
3.65
|
| Net Tangible Assets |
|
80.33
-43.26%
|
141.59
-19.65%
|
176.22
|
| Tangible Book Value |
|
80.33
-43.26%
|
141.59
-19.65%
|
176.22
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-51.26
+13.49%
|
-59.25
-0.41%
|
-59.01
-149.77%
|
118.57
|
| Cash Flow From Continuing Operating Activities |
|
-51.26
+13.49%
|
-59.25
-0.41%
|
-59.01
-149.77%
|
118.57
|
| Net Income From Continuing Operations |
|
-61.65
-14.08%
|
-54.04
+12.81%
|
-61.98
-152.59%
|
117.85
|
| Depreciation Amortization Depletion |
|
2.14
-9.50%
|
2.37
-2.11%
|
2.42
+1.34%
|
2.39
|
| Depreciation |
|
2.10
-4.16%
|
2.19
+2.82%
|
2.13
|
—
|
| Amortization Cash Flow |
|
0.05
-74.59%
|
0.18
-38.01%
|
0.29
|
—
|
| Depreciation And Amortization |
|
2.14
-9.50%
|
2.37
-2.11%
|
2.42
+1.34%
|
2.39
|
| Amortization Of Intangibles |
|
0.05
-74.59%
|
0.18
-38.01%
|
0.29
|
—
|
| Other Non Cash Items |
|
3.18
+144.28%
|
-7.19
-934.84%
|
0.86
+168.66%
|
-1.25
|
| Pension And Employee Benefit Expense |
|
-0.55
+18.51%
|
-0.67
-225.23%
|
0.54
-53.36%
|
1.15
|
| Stock Based Compensation |
|
4.42
+7.65%
|
4.11
-21.16%
|
5.21
+2.34%
|
5.09
|
| Deferred Tax |
|
0.00
+0.00%
|
0.00
|
0.00
|
0.00
|
| Deferred Income Tax |
|
0.00
+0.00%
|
0.00
|
0.00
|
0.00
|
| Operating Gains Losses |
|
-0.55
+18.51%
|
-0.67
-225.23%
|
0.54
-53.36%
|
1.15
|
| Change In Working Capital |
|
1.21
+131.87%
|
-3.80
+36.82%
|
-6.01
+0.00%
|
-6.01
|
| Change In Receivables |
|
0.48
+239.77%
|
-0.35
+62.81%
|
-0.93
-103.69%
|
25.26
|
| Change In Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Change In Payables And Accrued Expense |
|
0.41
-40.44%
|
0.69
+189.31%
|
-0.77
+90.13%
|
-7.77
|
| Change In Accrued Expense |
|
0.34
+113.04%
|
0.16
+257.78%
|
0.04
+101.85%
|
-2.43
|
| Change In Payable |
|
0.07
-87.60%
|
0.52
+164.53%
|
-0.81
+84.79%
|
-5.34
|
| Change In Account Payable |
|
—
|
0.52
+164.53%
|
-0.81
+84.79%
|
-5.34
|
| Change In Other Working Capital |
|
-0.02
+99.59%
|
-4.37
+23.75%
|
-5.73
+77.33%
|
-25.29
|
| Change In Other Current Assets |
|
0.34
+41.35%
|
0.24
-83.36%
|
1.42
-20.31%
|
1.79
|
| Investing Cash Flow |
|
72.55
+79.20%
|
40.49
-9.30%
|
44.64
+144.14%
|
-101.12
|
| Cash Flow From Continuing Investing Activities |
|
72.55
+79.20%
|
40.49
-9.30%
|
44.64
+144.14%
|
-101.12
|
| Net PPE Purchase And Sale |
|
-0.71
-1.28%
|
-0.70
-22.61%
|
-0.57
+51.15%
|
-1.18
|
| Purchase Of PPE |
|
-0.71
-1.28%
|
-0.70
-22.61%
|
-0.57
+51.15%
|
-1.18
|
| Capital Expenditure |
|
-0.71
+1.24%
|
-0.72
+10.52%
|
-0.81
+42.98%
|
-1.42
|
| Net Investment Purchase And Sale |
|
71.54
+93.50%
|
36.97
-11.17%
|
41.62
+141.54%
|
-100.20
|
| Purchase Of Investment |
|
-66.28
+72.39%
|
-240.04
+13.60%
|
-277.82
+7.21%
|
-299.42
|
| Sale Of Investment |
|
137.81
-50.25%
|
277.01
-13.28%
|
319.44
+60.35%
|
199.22
|
| Net Intangibles Purchase And Sale |
|
0.00
+100.00%
|
-0.02
+92.27%
|
-0.23
+2.92%
|
-0.24
|
| Purchase Of Intangibles |
|
0.00
+100.00%
|
-0.02
+92.27%
|
-0.23
+2.92%
|
-0.24
|
| Financing Cash Flow |
|
-1.15
-107.96%
|
14.43
+1336.76%
|
-1.17
+25.67%
|
-1.57
|
| Cash Flow From Continuing Financing Activities |
|
-1.15
-107.96%
|
14.43
+1336.76%
|
-1.17
+25.67%
|
-1.57
|
| Net Issuance Payments Of Debt |
|
-1.21
-0.33%
|
-1.21
-0.83%
|
-1.20
-0.76%
|
-1.19
|
| Repayment Of Debt |
|
-1.21
-0.33%
|
-1.21
-0.83%
|
-1.20
-0.76%
|
-1.19
|
| Long Term Debt Payments |
|
-1.21
-0.33%
|
-1.21
-0.83%
|
-1.20
-0.76%
|
-1.19
|
| Net Long Term Debt Issuance |
|
-1.21
-0.33%
|
-1.21
-0.83%
|
-1.20
-0.76%
|
-1.19
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
17.34
|
0.00
+100.00%
|
-0.63
|
| Common Stock Payments |
|
—
|
0.00
|
0.00
+100.00%
|
-0.63
|
| Repurchase Of Capital Stock |
|
—
|
0.00
|
0.00
+100.00%
|
-0.63
|
| Proceeds From Stock Option Exercised |
|
0.06
+57.50%
|
0.04
+29.03%
|
0.03
-87.60%
|
0.25
|
| Net Other Financing Charges |
|
—
|
-1.74
|
—
|
—
|
| Changes In Cash |
|
20.14
+565.30%
|
-4.33
+72.13%
|
-15.54
-197.86%
|
15.88
|
| Effect Of Exchange Rate Changes |
|
-1.36
-252.57%
|
0.89
+117.52%
|
-5.10
-2077.52%
|
0.26
|
| Beginning Cash Position |
|
63.87
-5.10%
|
67.31
-23.47%
|
87.95
+22.47%
|
71.81
|
| End Cash Position |
|
82.65
+29.40%
|
63.87
-5.10%
|
67.31
-23.47%
|
87.95
|
| Free Cash Flow |
|
-51.97
+13.34%
|
-59.97
-0.26%
|
-59.81
-151.06%
|
117.15
|
| Common Stock Issuance |
|
0.00
-100.00%
|
17.34
|
0.00
|
0.00
|
| Interest Paid CFO |
|
-0.02
+30.77%
|
-0.03
+23.53%
|
-0.03
+94.74%
|
-0.65
|
| Interest Received CFI |
|
1.73
-59.26%
|
4.24
+10.77%
|
3.83
+674.70%
|
0.49
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
17.34
|
0.00
|
0.00
|
| Taxes Refund Paid |
|
—
|
0.00
|
0.00
|
0.00
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|